How to Participate in the Elaboration and Revision of Monographs

Dr Mihaela Buda
European Pharmacopoeia Department
EDQM, Council of Europe
Basis for Monographs

- Monographs must take account of all currently approved products
- Approved specification(s) are the main basis backed up by batch data
- Draft monographs are checked by users including regulatory authorities at Pharmeuropa stage
- Policy for monograph development is given in: *Technical Guide for the Elaboration of Monographs* (available on the EDQM website)

Creation or Revision of a text

Chair of the Ph. Eur. Commission
Delegation of a member state
Experts, EDQM

[Diagram showing the process of creation or revision of a text]

Publication → Text adopted by the Commission → Request for creation / revision → Approval by the Commission → Allocation to a Working Procedure → Assignment to a group of experts → Public enquiry in Pharmeuropa → Creation / revision of the text by the Group → Text adopted by the Commission → Publication
How to Request a Revision?


Proposing a New Monograph

⇒ Contact the EDQM [in Europe: National Pharmacopeia Authority]

✓ Initial data: countries (in Europe) where the product is approved

✓ Data package:
  • Current specifications
  • Analytical procedures (SOPs)
  • Method validation reports
  • Batch and stability data
  • Samples of the finished product, substance and impurities
  • Full description of data package is available
Data for Revision

- Revision can only be undertaken if the request is backed up by sufficient data
- Provide batch data, sample chromatograms, etc. to enable a decision on the need for revision
- Supply validated methods (if possible, cross-validated against official Ph. Eur. method) and samples notably for all impurities controlled by the new method
And then?

- **Outside Ph. Eur. Member states:**
  - Contact EDQM which will refer the matter to a group of experts or to the Ph. Eur. Commission

- **Ph. Eur. Member states:**
  - Via National Pharmacopoeia Authority (address list on EDQM website and in Pharmeuropa)

Make clear what needs revising and, if possible, make a **concrete proposal**

---

Revision: Why?

- **Developments in Regulatory Environment**
  - E.g. Guidelines, ICH Q3D, elemental impurities
  - ICH Q8/Q9/Q10/Q11, REACH

- **Scientific / technical evolutions**
  - E.g. Fast LC, PAT, new molecules, new therapies e.g. CT

- **Increased demand for Generic and Biosimilar products**
  - E.g. New sources

- **New risks to Public Health**
  - E.g. Genotoxic impurities, TSE, contamination/falsification (heparins)

- **Developments in Manufacture and Globalisation**
  - E.g. Continuous manufacturing, changed routes of synthesis

- Need to regularly review and update Ph. Eur. texts
  - Need to create new texts
Creation or Revision of a Text

Chair of the Ph. Eur. Commission
Delegation of a member state
Experts, EDQM

Publication
Request for creation / revision
Approval by the Commission
Allocation to a Working Procedure

Text adopted by the Commission
Public enquiry in Pharmeuropa
Creation / revision of the text by the Group
Assignment to a Group of experts

Revision Programme

✓ Work programme is announced via EDQM website and to industry associations and pharmacopoeia liaison contacts

✓ Stakeholders to:
  • Declare an interest for relevant items
  • Make sure Pharmeuropa is seen for revision proposals
  • Provide samples, test draft proposal
How are Texts Elaborated / Revised?

- **Procedure 1** (Group of experts):
  - Multi-source products and monograph revisions
  - On request, data are handled confidentially by EDQM

- **Procedure 4** (Group of regulators):
  - Single-source products, direct co-operation with innovator
  - Data are handled confidentially by EDQM
**P4 Procedure: Aim**

- Create monographs for *single-source* substances/finished products (still under patent) with a potential for further generics
- Based on authorised products
- Monograph ready ≥ 2 years before patent expiry (ideally)
- Possibility of starting elaboration work 5 years after first MA approval
- Protection of *proprietary information*: expert group P4 solely composed of regulators, OMCLs and EDQM

---

**Creation or Revision of a Text**

Chair of the Ph. Eur. Commission  
Delegation of a member state  
Experts, EDQM

- Text adopted by the Commission  
- Request for creation / revision  
- Approval by the Commission  
- Allocation to a Working Procedure  
- Assignment to a Group of experts  
- Creation / revision of the text by the Group  
- Presentation of the draft text in Pharmeuropa  
- Text adopted by the Commission  
- Publication
By Whom?

✓ **Groups of experts and working parties** – appointed by the Ph. Eur. Commission

✓ **800 experts** in pharmaceutical sciences from the Ph. Eur. members states and observers

✓ The Ph. Eur. Commission has revised its working procedures to open up to the nomination of experts from non-European Pharmacopoeia member states and non-observers states

Creation or Revision of a Text

Chair of the Ph. Eur. Commission
Delegation of a member state
Experts, EDQM
Creation or Revision of a Text

Chair of the Ph. Eur. Commission
Delegation of a member state
Experts, EDQM

Text adopted by the Commission

Publication

Request for creation / revision

Approval by the Commission

Allocation to a Working Procedure

Assignment to a Group of experts

Public enquiry in Phareuropa

Creation / revision of the text by the Group
Adoption of the Text (New or Revised)

- Submission to Ph. Eur. Commission for adoption
- Publication in the Ph. Eur.
- Implementation 1 year after adoption (see publication schedule available on website)

Overall timescale: minimum 2 years
Including 5 months for public enquiry and at least 6 months between adoption and publication

After Revision: Why?

FAQ: “Why did you revise the monograph on...?”

⇒ The answer can be found out via:
  - Briefing notes in Pharmeuropa
  - Collected briefing notes posted on the website for each new edition/supplement (http://pharmeuropa.edqm.eu/home/menupage/English/Useful%20Information/Supplementcomments82.pdf)
  - Knowledge database (monograph history)

No briefing notes for corrections
Monograph under Elaboration

- The monograph has been authorised but work has not started yet
- The monograph has been authorised for publication in Pharmeuropa (see Pharmeuropa number)
- The monograph has been submitted for adoption to the European Pharmacopoeia Commission
- The monograph has been adopted
- The monograph is about to be published, or has been published (see the supplement number indicated and the calendar of the editions below)

The number of the last issue of Pharmeuropa into which a draft of the monograph was published

The section reflects the status of the text with regard to the work of:
- the Pharmacopoeia Discussion Group (PDG), a joint collaboration between the United States Pharmacopeia, the Japanese Pharmacopoeia and the European Pharmacopoeia.
- the International Conference on Harmonisation (ICH) Quality Guideline on Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH (Q4B).

Further information can be found in chapter 5.8 (Pharmacopoeial Harmonisation) of the European Pharmacopoeia.

---

Monograph under Revision

- Aim of the revision
- State of work
- The number of the last issue of Pharmeuropa into which a draft of the monograph was published

For guidance purposes: provides additional information to users e.g. column / trade names

Additional information: not available

History: contains information concerning certain technical modifications to some revised/corrected texts published since Ph. Eur. 5.0. This information complements the modifications indicated by lines in the margin in the supplements and is not necessarily exhaustive.

If certificate(s) of suitability have been granted for the substance in question, their list is shown. This is an excerpt from the online List of CEP.
**Ph. Eur. Monograph Elaboration/Revision: to Summarise**

### Monographs are based on quality described for registered products

**Call for interest**

1. Request for monograph elaboration/revision
2. Endorsement by the Ph. Eur. Commission
3. Assignment to a Group of Experts
4. Creation/revision of the text by the Group
5. Public enquiry in Pharmeuropa

- **Data package**
  - (current specifications, analytical procedures; validation data; batch and stability data)
- **Material** for testing
  - Candidate material for RS establishment

- **Review of data package**
- **Draft monograph development**
- **Laboratory study/collaborative testing — all preparations** (protocol preparation; method verification; data analysis)
- **Draft published for comments**
  - (testing of draft monograph) — 3 months commenting period
- **Evaluation of stakeholder feedback** (technical comments, data)

### Pharmacopoeia Liaison

- EDQM wishes to have a pharmacopoeia liaison contact for each major manufacturer/user
- Channel information and requests from manufacturer to EDQM
- Reception point for contact by EDQM
- Benefits for both sides

---

©2019 EDQM, Council of Europe. All rights reserved.
Thank you for your attention

Stay connected with the EDQM

EDQM Newsletter: https://go.edqm.eu/Newsletter
LinkedIn: https://www.linkedin.com/company/edqm/
Twitter: @edqm_news
Facebook: @EDQMCouncilofEurope